Saturday, March 17, 2018

IpadAndIphoneCVILLEMarApr2018 Click here
for the latest
digital edition
of OurHealth

Featured Stories

Kohl’s Donating $250,000 to UVA Children’s Hospital for Healthy Living Programs

Kohl’s Cares is donating $250,000 over two years to the Kohl’s Hoo’s Fit program at the University of Virginia Children’s Hospital to support healthy eating and active living in school-age children.

Overseen by the UVA Children’s Fitness Clinic (CFC), Kohl’s Hoo’s Fit includes two free programs that go directly into after school programs and community centers: Healthy Eating and Active Living (HEAL) and the Go Girls & Guys! Community program. HEAL is a six-week class led by UVA School of Medicine students in the Social Issues in Medicine Course that teaches children about healthy nutrition and the importance of physical activity. Go Girls and Guys! Community Program is a six-week program that includes 30 minutes of Zumba instruction each week followed by wellness discussions.

Also available through Kohl’s Hoo’s Fit is the Exceptional Kids’ Club, a free fitness program at UVA Children’s Hospital for children with autism spectrum disorder. This program also includes child wellness education sessions for parents led by UVA experts, which include the CFC and UVA’s Kinesiology of Individuals with Disabilities Program at the UVA Curry School of Education. 

Promoting healthy eating and active living is an identified priority area for improvement in the recently published 2016 MAPP2Health community health assessment and health improvement plan for Central Virginia.

“Through this comprehensive approach, our goal is to reach thousands of children in our community each year and help them form healthy habits that last a lifetime,” said Anna King, CTRS, CFC’s outreach coordinator.

For more information about these programs, please call 434.982.1607.

Kohl's donation to UVA Children’s Hospital is made possible through the Kohl's Cares cause merchandise program. Through this initiative, Kohl’s sells $5 books and soft toys, where 100 percent of net profit benefits children’s health initiatives nationwide, including hospital partnerships like this one. Kohl's has raised more than $317 million through this merchandise program. Since 2005, Kohl’s has donated more than $560,000 to UVA Children’s Hospital. For more information, call 434.982.1607.

About Kohl’s

Kohl’s (NYSE: KSS) is a leading omnichannel retailer with more than 1,100 stores in 49 states. With a commitment to inspiring and empowering families to lead fulfilled lives, Kohl’s offers amazing​​ national and exclusive brands, incredible savings and an easy shopping experience in our stores, online at and on Kohl's mobile app. ​Throughout its history, Kohl's has given nearly $600 million to support communities nationwide. For a list of store locations or to shop online, visit For more information about Kohl’s impact in the community and how to join our winning team, visit


UVA Health System is an academic health system that includes a 612-bed hospital, the UVA School of Medicine, a level I trauma center, nationally recognized cancer and heart centers and primary and specialty clinics throughout Central Virginia. UVA is recognized for excellence by U.S. News & World Report, Best Doctors in Americaand America's Top Doctors.

Related items

  • CHKD, UVA Form Network to Enhance Pediatric Care in Virginia

    University of Virginia Children's Hospital and Children's Hospital of The King's Daughters will establish a clinically integrated network (CIN) dedicated exclusively to improving children’s health. This CIN, the only one in Virginia designed specifically for pediatrics, will initially serve children throughout greater Hampton Roads and Charlottesville and its neighboring counties.

    The physician-led network, a joint venture of CHKD and UVA Children’s Hospital, will unite pediatric healthcare providers -- pediatricians, pediatric specialists, pediatric surgeons and others essential to the care of children -- to develop protocols, practices and standards of care. Their goal: ensuring all children have easy access to the best care in the right location with the greatest efficiency and value.

    "Our goal is to develop a model of pediatric care that delivers superior care coordination and clinical outcomes to patients while supporting the practices of participating providers through clinical integration, innovation, research and education," said Richard P. Shannon, MD, executive vice president for health affairs at UVA.  

    Clinically integrated networks are designed to improve the health of patients and reduce costs through care coordination by implementing physician-designed clinical standards and linking physicians, hospitals, other care providers and insurers to work toward these common goals. "Clinical networks will become increasingly important as the Virginia Medicaid program transitions to a platform that focuses on innovation, establishes alternative payment models and monitors both utilization and care outcomes," said Jim Dahling, president and CEO of CHKD Health System.

    This announcement is the culmination of extensive collaboration, analysis and preparation by both institutions, which have also partnered on a regional collaborative for cardiac care. CHKD and UVA will work with physicians and community partners to help define and design the roadmap for the CIN.

    "The input and expertise of pediatricians, specialists, and surgeons from UVA and CHKD as well as partners in the community will be essential to our success as we work together to improve the health of our children through this network," Dahling said.

    About CHKD

    CHKD is the only freestanding children’s hospital in Virginia and serves the medical and surgical needs of children throughout greater Hampton Roads, the Eastern Shore of Virginia and northeastern North Carolina. The not-for-profit CHKD Health System operates primary care pediatric practices, surgical practices, multi-service health centers, urgent care centers and satellite offices throughout its service region. For more information, visit

    About UVA Children’s Hospital

    University of Virginia Children’s Hospital provides primary and specialty care in more than 30 specialties to children throughout Virginia. UVA Children’s Hospital includes 111 beds, a dedicated pediatric emergency department, a neonatal intensive care unit for infants, and a pediatric intensive care unit. The Battle Building, which opened in 2014, consolidates outpatient children’s care at a single location in Charlottesville. U.S. News & World Report has nationally ranked UVA Children’s Hospital in four specialties – cardiology and heart surgery, diabetes and endocrinology, neonatology and orthopedics.


    UVA Health System is an academic health system that includes a 612-bed hospital, the UVA School of Medicine, a level I trauma center, nationally recognized cancer and heart centers and primary and specialty clinics throughout Central Virginia. UVA is recognized for excellence by U.S. News & World Report, Best Doctors in Americaand America's Top Doctors.

  • Teen 1st in Va. to Receive Cancer Gene Therapy in UVA Clinical Trial

    The University of Virginia Health System has administered its first dose of an experimental immunotherapy for pediatric acute lymphoblastic leukemia that has resisted other forms of treatment.

    The approach, known as chimeric antigen receptor (CAR) T-cell therapy, takes a person’s own immune cells and genetically modifies them with the goal of making them more effective cancer killers. In this case, pediatric oncologist Daniel “Trey” Lee, MD, of the UVA Children’s Hospital, the UVA Cancer Center and UVA’s Carter Immunology Center, took the immune cells from a 14-year-old clinical trial participant with a form of cancer known as primary refractory acute lymphoblastic leukemia. The trial participant’s immune cells were then genetically engineered by the cell therapy company Kite Pharma before Lee infused them back into the teen.

    The experimental approach is similar to the gene therapy that the federal Food and Drug Administration approved for pediatric lymphoblastic leukemia at the end of August – the first gene therapy ever approved in the United States – but Lee hopes the new approach will offer advantages for patients.

    “We collect cells from a vein of a patient, the cells are shipped to a central manufacturing facility where they’re made in approximately seven days, and they’re shipped back to us,” Lee said. “So we can have a vein-to-vein time of 16 to 18 days, which is really fast.”

    Testing Effectiveness

    While at the National Institutes of Health, Lee tested the approach using a similar product in more than 50 trial participants. Those participants saw a response rate of approximately 70 percent and a relapse rate of less than 10 percent, he said. The results of the current testing will be available when the 20-site clinical trial has concluded, possibly in less than two years. 

    UVA recruited Lee from the NIH based on his pioneering research into the development of what are called CAR T-cell therapies, named for the immune cells that are genetically engineered. In addition to the leukemia therapy, he is also seeking to develop new T-cell therapies for deadly forms of pediatric brain cancer. At UVA, he joins a world-class team of researchers exploring the potential of immunotherapy to enhance the body’s ability to fight off disease. “You will see a lot more CAR T-cell treatments coming out of UVA in the future,” he said.

    Pediatric Lymphoblastic Leukemia Clinical Trial

    The phase I/II lymphoblastic leukemia trial is evaluating the safety and effectiveness of the approach in pediatric patients. The trial will look at the overall remission rate, the duration of remission and overall survival after 12 months, among other factors.

    Participants must be between the ages of 2 and 21 and have lymphoblastic leukemia that has relapsed or not responded to other forms of treatment. There are other eligibility requirements as well.

    For more information, visit UVA’s clinical trial site. The trial is IRB No. 19087.


    UVA Health System is an academic health system that includes a 612-bed hospital, the UVA School of Medicine, a level I trauma center, nationally recognized cancer and heart centers and primary and specialty clinics throughout Central Virginia. UVA is recognized for excellence by U.S. News & World Report, Best Doctors in Americaand America's Top Doctors.

  • What is Tetralogy of Fallot?

    Tetralogy of fallot is a congenital heart defect consisting of a ventricular septal defect (hole between the pumping chambers) and obstruction to outflow of blood from the right side of the heart. If left untreated, this condition causes cyanosis, or a reduced oxygen level, and shortens life.

    Tetralogy is the most common cyanotic congenital heart defect. Surgical repair has been available for several decades. The original surgical procedure for affected infants was a shunt connecting a branch of the aorta to the lung artery. This improved the oxygen level to allow growth until the child was large enough to undergo complete repair.

    Complete repair consists of closing the ventricular septal defect and removing obstructive tissue to enable blood to leave the right side of the heart. With improvements in infant heart surgery, this condition is now commonly repaired in infancy without having a prior shunting procedure. The child’s oxygen level is normal after surgery, and their ability to exercise is much improved.

    Thomas L’Ecuyer, MD
    Pediatric Cardiologist
    UVA Children’s Hospital and UVA Heart & Vascular Center
    Charlottesville | 434.924.0408

cville store